# A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)

> **NCT06630234** · PHASE1,PHASE2 · RECRUITING · sponsor: **Deciphera Pharmaceuticals, LLC** · enrollment: 120 (estimated)

## Conditions studied

- Gastrointestinal Stromal Tumor (GIST)

## Interventions

- **DRUG:** DCC-3009

## Key facts

- **NCT ID:** NCT06630234
- **Lead sponsor:** Deciphera Pharmaceuticals, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-10
- **Primary completion:** 2028-05
- **Final completion:** 2028-05
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06630234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06630234, "A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06630234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*